Johnson & Johnson Appoints Senior Leaders to Executive Committee
NEW BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the appointment of a number of senior leaders to the Company's Executive Committee.
Specifically:
Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals, and Dr. Paul Stoffels, Executive Vice President, Chief Scientific Officer of Johnson & Johnson have been appointed to the position of Vice Chairman of the Executive Committee, effective July 2, 2018. Mr. Duato and Dr. Stoffels will continue to report to Alex Gorsky, Chairman of the Board and Chief Executive Officer of Johnson & Johnson.
In his role as Vice Chairman of the Executive Committee, Mr. Duato will be responsible for the Pharmaceuticals and Consumer sectors, as well as Supply Chain, IT, Global Services, and the Health and Wellness businesses.
In his role as Vice Chairman of the Executive Committee, Dr. Stoffels will be responsible for Pharmaceutical Research & Development, Global Public Health, the Office of the Chief Medical Officer, External Innovation, Pharmaceuticals Business Development and Healthcare Technology.
Ashley McEvoy, Company Group Chairman, Consumer Medical Devices, has been appointed Executive Vice President, Worldwide Chairman, Medical Devices, effective July 2, 2018. She will report to Mr. Gorsky and become a member of the Executive Committee.
Jennifer Taubert, Company Group Chairman, The Americas, Pharmaceuticals, has been appointed Executive Vice President, Worldwide Chairman, Pharmaceuticals and named to the Executive Committee, effective July 2, 2018. She will report to Mr. Duato.
Kathy Wengel, Worldwide Vice President, Johnson & Johnson Supply Chain has been appointed Executive Vice President, Chief Global Supply Chain Officer, and named to the Executive Committee, effective July 2, 2018. She will report to Mr. Duato.
Michael Sneed, Worldwide Vice President, Global Corporate Affairs and Chief Communication Officer, will become Executive Vice President, Global Corporate Affairs and Chief Communication Officer and a member of the Executive Committee, effective July 2, 2018. Mr. Sneed will also assume responsibility for the Global Design group. He will continue to report to Mr. Gorsky.
"These appointments recognize the enormous talent among the senior leadership team of Johnson & Johnson, and will ensure our continued focus on delivering on our commitments to patients, consumers, employees, our communities and our shareholders," said Mr. Gorsky.
Separately, the Company announced today the retirement of Sandra (Sandi) E. Peterson, Group Worldwide Chairman. In addition, as previously announced Joseph Wolk, Vice President of Johnson & Johnson Investor Relations, has been appointed Executive Vice President, Chief Financial Officer and a member of the Executive Committee effective July 1, 2018.
About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Note to Investors Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and descriptions of risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Imaraïs Beauty and The Vitamin Shoppe® announced today the launch of an assortment of new wellness gummies, formulated to support the health and wellness goals of beauty consumers, exclusively at The Vitamin Shoppe and Super Supplements stores and on...
Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie)?announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow...
Addressing the issue of employee wellness in healthcare, the American Association for Physician Leadership (AAPL) has published a new book, Working Happy! How to Survive Burnout and Find Your Work/Life Synergy in the Healthcare Industry.
Author...
TDIndustries, a leading mechanical construction and facilities services firm, proudly announces that its Vice President of Environmental, Health and Safety Jamie Dabbs, CSP, ASP, CRIS, was named Construction Safety Professional of the Year by...
Nicklaus Children's Hospital this month attained Magnet recognition by the American Nurses Credentialing Center's Magnet Recognition Program® for the fifth consecutive term. Nicklaus Children's is one of only five children's hospitals in the nation...
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...